Superworth

Teva Pharmaceutical Industries forward PE TEVA

Share price divided by analysts' consensus earnings for the next twelve months, since 1995.

Today, Nov 3, 2026
15.3×
10-year median
5.4×
Against its 10-year history
94th
percentile: 0 is its lowest day, 100 its highest
10-year range
2.8× to 17.6×
Peer median
28.4×

Teva Pharmaceutical Industries' forward PE is 15.3× as of Nov 3, 2026.

That is above its ten-year median of 5.4×, higher than on 94% of days in the last ten years.

Over that time it ranged from 2.8× in Aug 2019 to 17.6× in Feb 2026.

The median for 10 healthcare stocks of a similar size is 28.4×.

Forward PE over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far14.6×12.5×17.6×
202517.1×5.6×17.1×
20249.3×4.5×9.3×
20234.2×3.0×4.7×
20223.8×2.8×4.6×
20213.2×3.2×5.1×
20203.9×3.1×5.7×
20194.3×2.8×8.6×
20186.9×6.6×10.8×
20177.0×4.1×9.1×
20168.1×8.1×13.2×
201513.6×11.6×14.5×
201411.8×8.1×12.0×
20138.1×7.4×8.4×
20127.6×7.6×8.7×
20117.4×6.5×11.9×
201011.3×10.7×15.3×
200913.9×12.9×15.4×
200813.9×13.7×19.9×
200719.0×15.3×19.0×

Against its peers

Companies in Healthcare nearest Teva Pharmaceutical Industries' size, closest first, today.

CompanyForward PE
TEVATeva Pharmaceutical Industries15.3×
AAgilent Technologies26.8×
HUMHumana33.0×
MDLNMedline22.7×
WATWaters30.4×
IQVIQVIA19.0×
IDXXIDEXX Laboratories42.4×
EWEdwards Lifesciences30.1×
BDXBecton, Dickinson and15.0×
ONCBeOne Medicines45.0×
RPRXRoyalty Pharma13.6×
Peer median28.4×

Where Teva Pharmaceutical Industries ranks

What the forward PE tells you

Price divided by what analysts expect the company to earn over the next twelve months. It answers "what am I paying for next year" instead of last year.

Estimates are opinions. When forward PE is far below trailing PE, analysts expect a big jump in earnings. If that jump slips, the stock was not as cheap as it looked.

More on Teva Pharmaceutical Industries

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.